EUVIMEDEUVIMED entdecken
Crossref

Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT

Wenwen Guo, Haixiao Zhang, Yawei Zheng, Hongye Gao, Weihua Zhai, Rongli Zhang, Qiaoling Ma, Donglin Yang, Yi He, Yonghui Xia, Aiming Pang, Sizhou Feng und 3 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05853-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Wenwen Guo und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clin…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Core Binding Factor Alpha 2 Subunit, Hematopoietic Stem Cell Transplantation, Epigenesis, Genetic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities Funds, National Natural Science Foundation of China, Key Project of Tianjin Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteCore Binding Factor Alpha 2 SubunitHematopoietic Stem Cell TransplantationEpigenesis, GeneticHumansFemaleMaleMiddle AgedAdultProspective StudiesRUNX1 Translocation Partner 1 ProteinBenzamidesNeoplasm, ResidualYoung AdultAdolescentAllograftsAzacitidineAminopyridines

Stichwörter der Autor:innen

Acute myeloid leukemiaHematopoietic stem cell transplantationPreemptive therapyProphylactic therapyRUNX1::RUNX1T1

Substanzen

Core Binding Factor Alpha 2 SubunitRUNX1 protein, humanRUNX1 Translocation Partner 1 ProteinBenzamidesRUNX1T1 protein, humanN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideAzacitidineAminopyridines

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin, 301600, China.
  • Tianjin Institutes of Health Science, Tianjin, 301600, China. caoyigeng@ihcams.ac.cn.

Förderung

  • Fundamental Research Funds for the Central Universities Funds
  • National Natural Science Foundation of China
  • Key Project of Tianjin Natural Science Foundation
  • Tianjin Health Science and Technology Project
  • Haihe Laboratory of Cell Ecosystem Innovation Fund

Zitieren

APA

Guo, W., Zhang, H., Zheng, Y., Gao, H., Zhai, W., Zhang, R., Ma, Q., Yang, D., He, Y., Xia, Y., Pang, A., Feng, S., Han, M., Cao, Y., & Jiang, E. (2024). Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT. Annals of Hematology. https://doi.org/10.1007/s00277-024-05853-2

Vancouver

Guo W, Zhang H, Zheng Y, Gao H, Zhai W, Zhang R, et al. Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT. Annals of Hematology. 2024. doi:10.1007/s00277-024-05853-2

BibTeX
@article{Guo2024,
  author = {Guo, Wenwen and Zhang, Haixiao and Zheng, Yawei and Gao, Hongye and Zhai, Weihua and Zhang, Rongli and Ma, Qiaoling and Yang, Donglin and He, Yi and Xia, Yonghui and Pang, Aiming and Feng, Sizhou and Han, Mingzhe and Cao, Yigeng and Jiang, Erlie},
  title = {Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05853-2}
}
Kostenlos starten →